Abstract
Somatic mutations in cancer give rise to neoantigens. Technology revolutions in cancer genomics and immunology have made it possible to rapidly identify neoantigens for cancer vaccines. Leisegang and colleagues report that it is practical to rapidly identify neoantigens for adoptive T-cell therapy in a mouse tumor model. Clin Cancer Res; 22(11); 2602-4. ©2016 AACRSee related article by Leisegang et al., p. 2734.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have